Early cost-effectiveness model of whole genome sequencing as a molecular diagnostic test versus standard of care in locally advanced and metastatic (Stage IIIB,C/ IV) non-squamous non-small cell lung cancer

Results

WGS as a diagnostic test resulted in more QALYs (0.002) and costs (€1534 [incremental net monetary benefit –€1349]), and SoC followed by WGS resulted in fewer QALYs (–0.002) and more costs (€1059 [–€1194]) compared with SoC alone. WGS as a diagnostic test was only cost effective if it was priced at €2000 per patient and identified 2.7% more actionable patients than SoC alone. Treating these additional identified patients with new treatments costing >€4069 per month decreased the probability of cost effectiveness.

Conclusion

Our analysis suggests that providing WGS as a diagnostic test would be cost effective compared with SoC followed by WGS and SoC alone if costs for WGS decreased and additional patients with actionable targets were identified. This cost-effectiveness model can be used to incorporate new findings iteratively and to support ongoing decision making regarding the use of WGS in this rapidly evolving field.

Source File(s)

Summary